Objective: The aims of this study were to generate normal values of aminoterminal pro-brain natriuretic peptide in children with a bidirectional Glenn anastomosis without congestive heart failure and to test the hypothesis that plasma levels of aminoterminal pro-brain natriuretic peptide correlate with the clinical severity of congestive heart failure and morbidity after the Fontan operation.
Atrial natriuretic peptide and brain natriuretic peptide (BNP) are natriuretic hormones secreted from the atrial and ventricular cardiac myocytes in response to an increase in ventricular wall stretch and filling pressures. 1 Hypoxia also has been shown to be a direct stimulus for secretion of atrial natriuretic peptide and BNP in human cardiac myocytes. 2 Concentrations of BNP and its biologically inactive aminoterminal fragment, aminoterminal pro-brain natriuretic peptide (NT-pro-BNP), are of high relevance in the diagnosis and treatment of adults with congestive heart failure (CHF). [3] [4] [5] [6] Several investigators established age-related reference values for BNP and NT-pro-BNP in healthy children. [7] [8] [9] Both peptides have been found to be useful markers in a variety of cardiac diseases in children and adolescents. [10] [11] [12] [13] [14] [15] Early and minor deteriorations of single-ventricle function are difficult to assess by means of echocardiographic analysis, and clinical signs usually appear very late. Therefore, it can be speculated that a laboratory parameter like NT-pro-BNP can help to detect CHF in patients with univentricular hearts. Thus far, data on the usefulness of natriuretic peptides in detecting heart failure in children with single-ventricle physiology after bidirectional Glenn (BDG) anastomosis are limited. [16] [17] [18] The aims of this prospective study were to generate normal values of NT-pro-BNP in children with BDG but without CHF and to test the hypothesis that preoperative plasma levels of NT-pro-BNP correlate with the severity of CHF, as well as with morbidity after the Fontan operation.
MATERIALS AND METHODS
From September 2004 to December 2007, NT-pro-BNP plasma levels of 78 patients after the BDG operation were measured with an automated enzyme immunoassay (Elecsys 2010; Roche Diagnostics, Basel, Switzerland). The study group included 33 patients who had their routine checkup appointment in the outpatient's clinic and 45 hospitalized patients who underwent either elective cardiac catheterization before the Fontan operation (41 patients) or catheter interventions (3 patients required dilatation of aortic coarctation, and 1 patient with hypoplastic left heart syndrome with severe insufficiency of the native aortic valve had placement of a plug into the left ventricular [LV] outflow tract). Because there is no special score available for assessment of heart failure in pediatric patients with univentricular hearts, the New York University Pediatric Heart Failure Index (NYUPHFI), 19 a general score for quantifying the severity of heart failure in children, was used. This score is a weighted linear combination of scores based on symptoms, physical signs, and medical regimen ( Table 1) . Healthy children without heart failure are expected to score low ( 2 points). In the NYUPHFI, having a singleventricle physiology scores withþ2 points, and therefore only a NYUPHFI score of 5 or greater was considered to reflect heart failure in patients after the BDG operation.
Age, sex, body weight, cardiac diagnoses, follow-up time after the BDG operation, serum creatinine level, NT-pro-BNP level, morphology of the systemic ventricle, NYUPHFI score, pulse oximetric saturation, and heart/chest ratio on chest radiographic analysis were analyzed in all patients. In the 45 patients who underwent cardiac catheterization, the following hemodynamic parameters were additionally recorded: increase in pressure over time (dp/dt) of the systemic ventricle, mean atrial pressure, and superior vena caval oxygen saturation. Parameters indicating postoperative morbidity (time to removal of chest tubes, length of stay in the intensive care unit, and total length of hospital stay) were analyzed in the 41 patients who underwent the Fontan operation.
The study complies with the Declaration of Helsinki, and informed consent was obtained from the guardian of each subject enrolled in the study.
All patient data were complete; there was no intention to replace missing data. For the subgroup comparison of the nonnormally distributed metric variable NT-pro-BNP (test of normality: Kolmogorov-Smirnov with Lilliefors significance correction) between groups, the nonparametric MannWhitney U test was used. Spearman's rank correlation coefficients were calculated. Data are reported as medians with ranges.
RESULTS
The study group included 50 male and 28 female patients with a median age of 3.2 years (range, 0.9-9.8 years) and a median weight of 14.7 kg (range, 5.9-25 kg). The median follow-up time after BDG anastomosis was 3 years (range, 0.6-5.4 years).
Anatomy and Surgical Procedures
Fifty-four patients had a systemic ventricle of right ventricular (RV) morphology, with hypoplastic left heart syndrome as the most common diagnosis (n ¼ 45); 20 patients had a systemic ventricle of LV morphology, with tricuspid atresia as the most common anatomy (n ¼ 12); and 4 patients had a systemic ventricle of undetermined morphology.
Surgical Procedures in Patients Without CHF
Forty-seven patients had a NYUPHFI score of less than 5 and were considered not to have CHF by the pediatric cardiologist, who was blinded to the NT-pro-BNP levels and the results of cardiac catheterization. Twenty-seven of 47 patients without CHF had a systemic RV morphology (20 cases of hypoplastic left heart syndrome and 7 cases of double-outlet right ventricle with transposition of the great arteries combined with either mitral or pulmonary atresia). As a primary palliative step, 18 of these patients had a Norwood stage I procedure with a right ventricle-pulmonary artery conduit, 5 patients had a Norwood stage I procedure with Blalock-Taussig shunt (BTS), 3 patients had a BTS, and 1 patient needed no operation before the BDG anastomosis. Eighteen of 47 patients had a systemic LV morphology (10 cases of tricuspid atresia, 4 cases of tricuspid atresia Heart failure severity is determined based on signs and symptoms, medical regimen, and ventricular physiology. Adding scores attributed to each individual criterion derives a total score. Scores can range from 0 (no heart failure) to 30 (severe heart failure). ACE, Angiotensin-converting Enzyme.
with transposition of the great arteries, 3 cases of pulmonary atresia with intact ventricular septum, and 1 case of doubleinlet left ventricle). In this systemic LV morphology group, the following surgical procedures were performed: 10 BTSs, 4 Norwood stage I procedures with a BTS, and 2 Norwood stage I procedures with a right ventricle-pulmonary artery shunt, and 2 patients needed no operation before BDG surgery. In summary, only 6 of 18 patients without CHF with a systemic LV morphology primarily required cardiac surgery compared with 23 of 27 patients with a systemic RV morphology.
Assessment of CHF and NT-Pro-BNP Levels
Thirty-one patients were considered to have clinical signs of CHF with a NYUPHFI score of 5 or greater (median, 6.5; range, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . The following signs of CHF were found in these 31 patients: abnormal ventricular function or relevant valve insufficiency by means of echocardiographic analysis (14 patients), edema (2 patients), failure to thrive (7 patients), cardiomegaly by means of radiographic analysis (27 patients), hepatomegaly (12 patients), sinus tachycardia (15 patients), retractions (2 patients), treatment with digoxin (3 patients), low-dose diuretics (23 patients), high-dose diuretics (8 patients), angiotensin-converting enzyme inhibitors (27 patients), and b-blocker medication (2 patients). In patients with clinical signs of CHF (31/78 patients), the NTpro-BNP levels were significantly higher (median, 670 pg/ mL; range, 290-39,763 pg/mL) than in patients without CHF (median, 171 pg/mL; range, 32-355 pg/mL; Table  2 ). NT-pro-BNP levels strongly correlated with the NYUPHFI score (P < .001; Figure 1 and Table 3 ), but no correlation was found between the follow-up time and NT-pro-BNP levels (Table 3) . Median oxygen saturation measured by means of pulse oximetry of the 47 patients without CHF was 83% (range, 71%-88%) and did not correlate with NT-pro-BNP levels ( Table 3) .
The 95th and the 97.5th percentile of NT-pro-BNP levels in patients without CHF were 334 pg/mL and 339 pg/mL, respectively. NT-pro-BNP levels in patients without CHF and a RV morphology of the systemic ventricle were significantly higher compared with those seen in patients with LV morphology of the systemic ventricle (Table 2) . Because renal function influences NT-pro-BNP levels, we ensured that patients had no signs of renal dysfunction and all serum creatinine levels were within the normal range, with a median of 0.31 mg/dL (range, 0.2-0.65 mg/dL).
Hemodynamic Data
Forty-five patients underwent cardiac catheterization. There was a positive correlation found between mean atrial pressure (median, 7 mm Hg; range, 4-15 mm Hg) and NTpro-BNP levels (Table 3) . dp/dt measurement of the systemic ventricle (median, 1005 mm Hg/s; range, 330-1445 mm Hg/s) and superior vena caval saturation (median, 67%; range, 56%-76%) negatively correlated with NTpro-BNP levels (Table 3) .
Outcome
Six patients with severe heart failure (NYUPHFI score, 10-19) had the highest NT-pro-BNP levels (1192-39,763 pg/mL). Four of these 6 patients died from heart failure during the study period, 1 patient underwent successful heart transplantation, and 1 patient remained stable with medical treatment. NT-pro-BNP levels were significantly higher (P < .001) in the 5 patients who died of heart failure or required heart transplantation when compared with those seen in the other study patients who did not reach these end points. NT-pro BNP concentration (pg/ml) FIGURE 1. Scatter plot of aminoterminal pro-brain natriuretic peptide (NT-pro-BNP) levels (x-axis) and New York University Pediatric Heart Failure Index scores (y-axis) in all 78 patients.
Outcome After the Fontan Operation
Forty-one patients of the study group underwent the Fontan operation. All received fenestrated Fontan tunnels, except 2 patients with significant pulmonary arteriovenous malformations. There were no early or late deaths in this group. Regarding postoperative morbidity, preoperative NT-pro-BNP levels positively correlated with time to removal of chest tubes (median, 9 days; range, 4-42 days) and length of total stay in the hospital (median, 17 days; range, 10-57 days) after the Fontan operation. The preoperative NT-pro-BNP levels did not correlate with the length of stay in the intensive care unit (median, 6 days; range, 1-34 days) after the Fontan operation.
DISCUSSION
In the present study NT-pro-BNP levels in patients later than 6 months after BDG anastomosis without signs of CHF were comparable with those reported in healthy children, with the same enzyme immunoassay test kit used ( Table 4 ). As previously reported by Holmgren and colleagues, 17 we found significantly higher NT-pro-BNP levels in patients with systemic RV morphology compared with those seen in patients with systemic LV morphology. This finding might reflect the fact that despite apparently normal ventricular function, the morphologic right ventricle might be more stressed as a systemic ventricle than the morphologic left ventricle. A further explanation for this finding might be that patients with systemic LV morphology experienced less neonatal cardiac surgeries and less placement of a right ventricle-pulmonary artery conduit compared with patients with systemic RV morphology.
NT-pro-BNP levels strongly correlated with the severity of CHF assessed with the NYUPHFI, as well as with hemodynamic signs of CHF invasively assessed by means of dp/ dt measurement. This was not surprising and is in accordance with previous studies on the usefulness of BNP and NT-pro-BNP levels in detecting heart failure and volume overload in patients with congenital heart disease. [10] [11] [12] [13] [14] [15] Especially in patients with univentricular hearts, quantitative assessment of ventricular function and early detection of dysfunction is of greatest importance but is still an unsolved problem. With regular measurements of NT-pro-BNP levels in the individual follow-up of patients after the BDG operation, clinicians might have an additional useful tool for early detection of CHF. However, NT-pro-BNP levels do not allow quantitative assessment of ventricular function. In this study the 97.5th percentile of NT-pro-BNP level in patients without CHF was found to be 339 pg/mL (295 pg/ mL in patients with RV morphology and 345 pg/mL in patients with LV morphology). In the routine follow-up of patients later than 6 months after the BDG operation, higher levels should lead to a careful work-up involving all available diagnostic modalities and to consideration of initiation NT-pro-BNP, Aminoterminal pro-brain natriuretic peptide; CHF, congestive heart failure; NYUPHFI, New York University Pediatric Heart Failure Index; F/U, follow-up; dp/dt, increase in pressure over time; SVO 2 , superior vena caval saturation; ICU, intensive care unit. or modification of a medical regimen. Because there was no correlation found between pulse oximetric saturation and NT-pro-BNP levels of patients without CHF, this study could not confirm the finding of Hopkins and associates 2 that hypoxia stimulates secretion of BNP. The finding that superior vena caval saturations measured during cardiac catheterization negatively correlate with NT-pro-BNP levels is not caused by increased NT-pro-BNP levels secondary to hypoxia; it more likely reflects low cardiac output in patients with CHF.
The preoperatively analyzed NT-pro-BNP levels correlated with the duration of excessive pleural fluid drainage after the Fontan operation, indicating that the presence of heart failure prolongs the adaption to the special hemodynamic conditions of any Fontan operation. We speculate that achieving normal preoperative NT-pro-BNP levels by optimizing medical treatment might result in less postoperative morbidity, especially in patients with clinically undetected heart failure. This hypothesis remains to be proved in future studies.
CONCLUSIONS
NT-pro-BNP levels of patients later than 6 months after BDG anastomosis without CHF should not exceed those of healthy children. Plasma NT-pro-BNP concentrations strongly correlate with the severity of heart failure after BDG anastomosis. Further studies are needed to determine whether NT-pro-BNP levels can aide clinicians in the early detection of CHF in this patient group. Patients with failure of normalization or an increase of NT-pro-BNP levels later than 6 months after surgical intervention should be carefully assessed for signs of heart failure and hemodynamic problems. Preoperative optimization of ventricular function might positively influence the postoperative morbidity of patients undergoing the Fontan operation.
